Anke van Erp, PhD, MSc
An immunohistochemistry (IHC) analysis of a large patient population demonstrated that several subtypes of difficult-to-treat sarcomas may respond to treatment with PD-1 pathway inhibiting immunotherapies, according to findings presented at the 2017 European Cancer Congress in Amsterdam1
Van Erp noted that this was the first time that high levels of PD-1 expression, either alone or in combination with PD-L1, were demonstrated on the tumors of DSRCT patients, who also showed co-expression of CD8+ cells. Co-chair of the session, Stefan Sleijfer of the Erasmus Medical Center in the Netherlands agreed that the high levels of PD-1, PD-L1, and CD8 expression in DSRCT warrants further investigation into whether PD-1 blockade could have clinical benefit in DSRCT patients.
- van Erp A, Versleijen-Jonkers Y, Hillebrandt-Roeffen M, et al. Exploring the potential for PD-1 blockade in sarcoma patients. Presented at: 2017 European Cancer Congress; January 27-30, 2017; Amsterdam, the Netherlands.
- Palmerini E, Agostinelli C, Picci P, et al. PD1 and PDL1 expression, tumoral microenvironment (TME) characterization and clinical implication in localized osteosarcoma. Presented at: 2016 ESMO Congress; October 7-10, 2016; Copenhagen, Denmark. Abstract 1399PD.
... to read the full story